CN2 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
High Profitability And MarginsSustained high gross and net margins indicate durable pricing power in specialty rare-disease drugs and efficient cost structure. Strong margins support reinvestment in R&D and patient support, fund potential M&A, and underpin long-term cash generation even if top-line growth slows.
Exceptionally Conservative Balance SheetMinimal debt and a growing equity base provide financial flexibility to fund product launches, absorb revenue volatility common in orphan drugs, and pursue strategic investments without refinancing risk. This conservatism reduces solvency risk and preserves optionality over the medium term.
Extended Firdapse Exclusivity (Patent Settlement)A settlement that delays generic entry to 2035 materially extends predictable cash flows from Firdapse, preserving a core revenue stream for years. That exclusivity horizon improves long-term revenue visibility and supports stable margins and internal investment planning.
Bears Say
Slowing Revenue GrowthRevenue growth has decelerated to near-flat TTM levels after prior rapid expansion, signaling that market penetration or product lifecycle gains may be exhausted. Sustaining return-on-equity and funding new initiatives will be harder without resumed top-line momentum or new product commercialization.
Recent Decline In Free Cash Flow GrowthAlthough absolute operating and free cash flow remain strong, the negative growth trend weakens the trajectory for internally funding R&D, launches, or bolt-on deals. If FCF volatility persists, management may face trade-offs between investment, dividends, or reliance on external financing.
Change-of-Control And Strategic UncertaintyAn imminent acquisition introduces durable strategic uncertainty: integration choices, reprioritization of programs, and potential restructuring could alter commercialization focus and capital allocation. For stakeholders, the loss of independent strategy may change long-term product prioritization and execution risk.
Catalyst Pharma News
CN2 FAQ
What was Catalyst Pharmaceutical Partners’s price range in the past 12 months?
Currently, no data Available
What is Catalyst Pharmaceutical Partners’s market cap?
Currently, no data Available
When is Catalyst Pharmaceutical Partners’s upcoming earnings report date?
Catalyst Pharmaceutical Partners’s upcoming earnings report date is Aug 12, 2026 which is in 31 days.
How were Catalyst Pharmaceutical Partners’s earnings last quarter?
Catalyst Pharmaceutical Partners released its earnings results on May 11, 2026. The company reported $0.404 earnings per share for the quarter, beating the consensus estimate of $0.384 by $0.02.
Is Catalyst Pharmaceutical Partners overvalued?
According to Wall Street analysts Catalyst Pharmaceutical Partners’s price is currently Undervalued.
Does Catalyst Pharmaceutical Partners pay dividends?
Catalyst Pharmaceutical Partners does not currently pay dividends.
What is Catalyst Pharmaceutical Partners’s EPS estimate?
Catalyst Pharmaceutical Partners’s EPS estimate is 0.39.
How many shares outstanding does Catalyst Pharmaceutical Partners have?
Currently, no data Available
What happened to Catalyst Pharmaceutical Partners’s price movement after its last earnings report?
Catalyst Pharmaceutical Partners reported an EPS of $0.404 in its last earnings report, beating expectations of $0.384. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Catalyst Pharmaceutical Partners?
Currently, no hedge funds are holding shares in CH:CN2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Catalyst Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.92 (― Downside)
$25.92 (― Downside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.02%
12-Months-Change
Fundamentals
Return on Equity
23.65%
Trailing 12-Months
Asset Growth
26.27%
Trailing 12-Months
Company Description
Catalyst Pharmaceutical Partners
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
CN2 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive performance narrative: strong double-digit revenue growth, record product and portfolio performance (notably FIRDAPSE and AGAMREE), robust profitability and cash generation, clear commercial execution improvements (patient identification, diagnostics, enrollment, and retention), and a constructive 2026 guidance range. Challenges were acknowledged—FYCOMPA's loss of exclusivity and revenue erosion, ongoing patent litigation, increasing royalties/milestones and gross-to-net pressure from IRA, and the need for additional label-supporting data for AGAMREE—all of which are being actively managed. On balance, highlights meaningfully outweigh the lowlights.View all CH:CN2 earnings summariesCN2 Stock 12 Month Forecast
Average Price Target
$25.92
Options Prices
Currently, No data available
---